---
schema_version: "secwatch.filing_event.v1"
accession: "0001655759-25-000008"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2025-02-11T23:59:59+00:00"
generated_at: "2026-05-26T23:23:24.533163+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arvinas reports Q4/FY2024 results; VERITAC-2 Phase 3 topline data expected in Q1 2025

## Summary
- Cash, cash equivalents and marketable securities $1,039.4M as of Dec 31, 2024; revenue $263.4M.
- VERITAC-2 Phase 3 monotherapy topline data in ER+/HER2- mBC anticipated in 1Q25; two new Phase 3 combos planned in 2025.
- ARV-102 (LRRK2 degrader) Phase 1 in Parkinson's initiated; SAD data in healthy volunteers to be presented at AD/PD in April 2025.
- Alex Santini appointed interim Chief Commercial Officer effective January 17, 2025.
- Cash runway sufficient into 2027; VERITAC-3 (vepdegestrant+palbociclib) discontinued beyond study lead-in.

## SEC filing metadata
- accession: 0001655759-25-000008
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2025-02-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000165575925000008/0001655759-25-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000165575925000008/arvn-20250211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001655759-25-000008
- JSON: https://secwatch.observer/filing/0001655759-25-000008.json
- Plain text: https://secwatch.observer/filing/0001655759-25-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.